![Truvada ([emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Japan Tobacco) Drug Overview 2019- Product Image](http://www.researchandmarkets.com/product_images/8219/8219235_500px_jpg/market_research_report.jpg)
Drug Overview
Truvada ([emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Japan Tobacco) is a once-daily, fixed-dose combination of two of Gilead’s marketed nucleoside reverse transcriptase inhibitors (NRTIs): Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate [TDF]). NRTIs block the action of the viral reverse transcriptase enzyme, preventing synthesis of viral DNA and subsequently inhibiting viral replication.
Truvada was the standard-of-care nucleos(t)ide reverse transcriptase inhibitor backbone for HIV-1 therapy for over a decade, but has now been largely replaced for the treatment of HIV by the successor NRTI backbone Descovy ([emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Japan Tobacco), which possesses reduced renal and bone toxicity. Truvada’s sales have also been negatively impacted by the launch of generics in the EU from September 2017, with EU sales falling from $644m in 2017 to $260m in 2018.
Truvada ([emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Japan Tobacco) is a once-daily, fixed-dose combination of two of Gilead’s marketed nucleoside reverse transcriptase inhibitors (NRTIs): Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate [TDF]). NRTIs block the action of the viral reverse transcriptase enzyme, preventing synthesis of viral DNA and subsequently inhibiting viral replication.
Truvada was the standard-of-care nucleos(t)ide reverse transcriptase inhibitor backbone for HIV-1 therapy for over a decade, but has now been largely replaced for the treatment of HIV by the successor NRTI backbone Descovy ([emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Japan Tobacco), which possesses reduced renal and bone toxicity. Truvada’s sales have also been negatively impacted by the launch of generics in the EU from September 2017, with EU sales falling from $644m in 2017 to $260m in 2018.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
